The U.S. Food and Drug Administration (FDA) has granted approval for leucovorin, a medication used to treat cerebral folate deficiency, for patients diagnosed with autism spectrum disorder. The approval is based on a review of over 40 patient data collected over a period of several years. This data included both adult and pediatric participants, examining the drug’s effects on symptoms related to folate deficiency. The FDA determined that leucovorin can improve neurological function and alleviate symptoms associated with this condition. This approval marks a step forward in managing this complex neurodevelopmental disorder.
Posted inBusiness
FDA Approves Leucovorin for Autism Treatment
